Novel bile acid therapeutics for the treatment of chronic liver diseases
Year: 2016
Type: review
Abstract: Recent developments in understanding the role of bile acids (BAs) as signalling molecules in human metabolism and inflammation have opened new avenues in the field of hepatology research. BAs are no longer considered as simple molecules helping in fat digestion but as agents with real therapeutic value in treating complex autoimmune and metabolic liver diseases. BAs and their receptors such as farnesoid X receptor, transmembrane G protein-coupled receptor 5 and peroxisome proliferator-activated receptor have been identified as novel targets for drug development. Some of these novel pharmaceuticals are already in clinical evaluation with the most advanced drugs having reached phase III trials. Chronic liver diseases such as primary biliary cholangitis, primary sclerosing cholangitis and nonalcoholic fatty liver disease, for which there is no or limited pharmacotherapy, are most likely to gain from these developments. In this review we discuss recent and the most relevant basic and clinical research findings related to BAs and their implications for novel therapy for chronic liver diseases.
Institution: Newcastle University
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Keywords: bile acids, bile acid signaling, chronic liver disease, farnesoid X receptor, TGR5, peroxisome proliferator-activated receptors, bile acid receptor agonists, primary biliary cirrhosis, primary sclerosing cholangitis, non-alcoholic fatty liver disease, drug development, inflammation, metabolism
Open Access status: green
OpenAlex ID: W2342384916
